Second Randomized Trial of Leukine® (sargramostim) in COVID-19 Demonstrates Improvement in Lung Function

Department of Defense (DOD) Sponsored U.S. Study Met Primary Endpoint for Improvement in Oxygenation and Demonstrated Treatment with Inhaled Leukine Was Safe and Well Tolerated

Lexington, MA – June 28, 2021 /PRNewswire/ — Partner Therapeutics, Inc. (PTx) announced top-line results of the U.S.-based iLeukPulm clinical trial of inhaled Leukine (sargramostim, yeast-derived recombinant human granulocyte macrophage colony stimulating factor (GM-CSF)) in hospitalized COVID-19 patients (NCT04411680).1  This prospective, randomized, controlled, open-label study was conducted at 11 U.S. hospitals.  The ...

Continue Reading →